Beyond platinum treatment for NSCLC: what does the future hold?

Beyond platinum treatment for NSCLC: what does the future hold?

Expert Rev Anticancer Ther. 2017 Jan 27;:

Authors: Santarpia M, Karachaliou N, Rosell R

Abstract
For the majority of patients without oncogene-driven non-small cell lung cancer (NSCLC), first-line platinum-based chemotherapy represented until recently the standard treatment approach. The recent understanding of the interactions between immune system and tumor growth has prompted the development of a new class of immunotherapeutic agents, the immune checkpoint inhibitors, specifically directed against the pathways exploited by tumor cells to suppress and evade the immune system. Immune checkpoint blockade (ICB) has demonstrated significant anti-tumor activity, with durable clinical responses and manageable toxicities. The identification and validation of predictive biomarkers for ICB remains crucial for the selection of patients, especially in the first-line setting. Novel synergistic combinations are currently being tested to further improve the therapeutic efficacy of these agents.

PMID: 28129003 [PubMed - as supplied by publisher]

http://ift.tt/2kElsxh